GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 275
- Registration Number
- NCT02605954
- Locations
- 🇺🇸
Capital Medical Associates, P.C., Washington, District of Columbia, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇮🇹Azienda Ospedale San Paolo, Monza, Italy
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 567
- Registration Number
- NCT02603120
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 578
- Registration Number
- NCT02603107
Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT02600351
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 55
- Registration Number
- NCT02600819
- Locations
- 🇦🇹
Otto Wagner Spital, Wien, Austria
🇫🇷Hopital Bichat-Claude Bernard, Paris, France
🇺🇸Mercer University School of Medicine, Macon, Georgia, United States
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 532
- Registration Number
- NCT02592057
- Locations
- 🇮🇳
Midas Institute of Gastro-enterology, Nagpur, Maharashtra, India
🇮🇳Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India
🇮🇳Artemis Hospital, Gurgaon, Haryana, India
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3294
- Registration Number
- NCT02591277
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT02579382
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 529
- Registration Number
- NCT02574455
- Locations
- 🇺🇸
Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States
🇺🇸Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States
🇺🇸Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02568683
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, NORD Pas-de-calais, France
🇫🇷Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France
🇫🇷Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France